<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_JUNHxAE">The long-term eff ect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study</title>
				<funder ref="#_FPZdfJV">
					<orgName type="full">CDC/WHO Cooperative Agreement</orgName>
				</funder>
				<funder ref="#_gE3W6Gs">
					<orgName type="full">unknown</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Prof</roleName><forename type="first">Guangwei</forename><surname>Li</surname></persName>
							<email>guangwei_li@medmail.com.cn</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Ping</forename><surname>Zhang</surname></persName>
							<email>pzhang@cdc.gov</email>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jinping</forename><surname>Wang</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Edward</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, Q Gong MD</roleName><forename type="first">Wenying</forename><surname>Yang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Qiuhong</forename><surname>Gong</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hui</forename><surname>Li</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hongliang</forename><surname>Li</surname></persName>
						</author>
						<author>
							<persName><roleName>BS</roleName><forename type="first">Yayun</forename><surname>Jiang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yali</forename><surname>An</surname></persName>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Ying</forename><surname>Shuai</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Bo</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jingling</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Theodore</forename><forename type="middle">J</forename><surname>Thompson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><forename type="middle">B</forename><surname>Gerzoff</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gojka</forename><surname>Roglic</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Yinghua</forename><surname>Hu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">H</forename><surname>Bennett</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, Y An MD</roleName><forename type="first">Ho</forename><surname>Li</surname></persName>
						</author>
						<author>
							<persName><roleName>MS, R B Gerzoff MS</roleName><forename type="first">J</forename><surname>Thompson</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hu</forename><surname>Li</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Funding Centers for Disease Control and Prevention , WHO , the China-Japan First Hospital.</note>
								<orgName type="department">Funding Centers for Disease Control and Prevention</orgName>
								<orgName type="institution">First Hospital</orgName>
								<address>
									<country>WHO the China-Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<note type="raw_affiliation">Department of Endocrinology , China-Japan Friendship Hospital , Beijing , China</note>
								<orgName type="department">Department of Endocrinology</orgName>
								<orgName type="institution">China-Japan Friendship Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">Division of Diabetes Translation , National Center for Chronic Disease Prevention and Health Promotion , Centers for Disease Control and Prevention , Atlanta , GA , USA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<orgName type="institution">National Center for Chronic Disease Prevention and Health Promotion</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Department of Cardiology , Da Qing First Hospital , Da Qing , China</note>
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Da Qing First Hospital</orgName>
								<address>
									<settlement>Da Qing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">Department of Chronic Diseases and Health Promotion , World Health Organization , Geneva , Switzerland (</note>
								<orgName type="department">Department of Chronic Diseases and Health Promotion</orgName>
								<orgName type="institution">World Health Organization</orgName>
								<address>
									<settlement>Geneva</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">G Roglic MD); and Phoenix Epidemiology and Clinical Research Branch , National Institutes of Health , National Institute of Diabetes and Digestive and Kidney Diseases , Phoenix , AZ , USA</note>
								<orgName type="department">G Roglic MD); and Phoenix Epidemiology and Clinical Research Branch</orgName>
								<orgName type="institution" key="instit1">National Institutes of Health</orgName>
								<orgName type="institution" key="instit2">National Institute of Diabetes and Digestive and Kidney Diseases</orgName>
								<address>
									<settlement>Phoenix</settlement>
									<region>AZ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Division of Diabetes Translation , National Center for Chronic Disease Prevention and Health Promotion , Centers for Disease Control and Prevention , Atlanta 30341 , GA , USA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<orgName type="institution">National Center for Chronic Disease Prevention and Health Promotion</orgName>
								<address>
									<postCode>30341</postCode>
									<settlement>Atlanta</settlement>
									<region>GA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">Department of Endocrinology , China-Japan Friendship Hospital , Beijing 100029 , China</note>
								<orgName type="department">Department of Endocrinology</orgName>
								<orgName type="institution">China-Japan Friendship Hospital</orgName>
								<address>
									<postCode>100029</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_cHr8wjm">The long-term eff ect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D729724D2D0594AC56B5120D08B4536F</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T06:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_vDdeTbx"><p xml:id="_FgczMDq"><s xml:id="_yjRtx5f">Background Intensive lifestyle interventions can reduce the incidence of type 2 diabetes in people with impaired glucose tolerance, but how long these benefi ts extend beyond the period of active intervention, and whether such interventions reduce the risk of cardiovascular disease (CVD) and mortality, is unclear.</s><s xml:id="_zz3ypMh">We aimed to assess whether intensive lifestyle interventions have a long-term eff ect on the risk of diabetes, diabetes-related macrovascular and microvascular complications, and mortality.</s><s xml:id="_QPY5r93">Methods In 1986, 577 adults with impaired glucose tolerance from 33 clinics in China were randomly assigned to either the control group or to one of three lifestyle intervention groups (diet, exercise, or diet plus exercise).</s><s xml:id="_TRaWCYr">Active intervention took place over 6 years until 1992.</s><s xml:id="_fwKqzUQ">In 2006, study participants were followed-up to assess the long-term eff ect of the interventions.</s><s xml:id="_Mc4zpVE">The primary outcomes were diabetes incidence, CVD incidence and mortality, and all-cause mortality.</s><s xml:id="_JCxvrWr">Findings Compared with control participants, those in the combined lifestyle intervention groups had a 51% lower incidence of diabetes (hazard rate ratio [HRR] 0•49; 95% CI 0•33-0•73) during the active intervention period and a 43% lower incidence (0•57; 0•41-0•81) over the 20 year period, controlled for age and clustering by clinic.</s><s xml:id="_wwcGpNu">The average annual incidence of diabetes was 7% for intervention participants versus 11% in control participants, with 20-year cumulative incidence of 80% in the intervention groups and 93% in the control group.</s><s xml:id="_wK7XEVJ">Participants in the intervention group spent an average of 3•6 fewer years with diabetes than those in the control group.</s><s xml:id="_5fJV5ty">There was no signifi cant diff erence between the intervention and control groups in the rate of fi rst CVD events (HRR 0•98; 95% CI 0•71-1•37), CVD mortality (0•83; 0•48-1•40), and all-cause mortality (0•96; 0•65-1•41), but our study had limited statistical power to detect diff erences for these outcomes.</s><s xml:id="_3DHrpZR">Interpretation Group-based lifestyle interventions over 6 years can prevent or delay diabetes for up to 14 years after the active intervention.</s><s xml:id="_eY4MQud">However, whether lifestyle intervention also leads to reduced CVD and mortality remains unclear.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zcezKVa">Introduction</head><p xml:id="_gnmT986"><s xml:id="_tRjNyP8">Major clinical trials in the USA, China, India, Finland, and Japan <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> have shown the eff ectiveness of lifestyle interventions to reduce the incidence of diabetes in people with impaired glucose tolerance.</s><s xml:id="_aVcc7Fy">Interventions designed to achieve modest weight loss and enhance behavioural change were eff ective across sex, age, and race or ethnicity groups, and over diff erent bodyweights.</s><s xml:id="_t6GpNKd">The interventions used group or individual counselling to reduce total dietary intake and saturated fat, increase dietary fi bre, exercise, and self-monitoring of behaviours.</s></p><p xml:id="_cYfg2aP"><s xml:id="_kyJRwBS">Despite these studies' importance as catalysts for new public health eff orts, important questions remain.</s><s xml:id="_WPhdzb8">How long does the reduction in the incidence of diabetes persist?</s><s xml:id="_WBD5Pqw">The Finnish Diabetes Prevention Study <ref type="bibr" target="#b5">6</ref> is known to have assessed this question, reporting that diabetes incidence was reduced for 3 years after the 4-year active intervention.</s><s xml:id="_A4Axfg3">Also unclear is how much the benefi ts of diabetes prevention extend to reducing the complications of diabetes, such as myocardial infarction, stroke, and mortality.</s></p><p xml:id="_9qvmfG6"><s xml:id="_dXWk6uG">The China Da Qing Diabetes Prevention Study 2 (CDQDPS) was the fi rst of these large-scale trials and examined the eff ect of diff erent lifestyle interventions in a group setting among Chinese people with impaired glucose tolerance.</s><s xml:id="_Skss6PK">We report the results from a 20-year follow-up of the CDQDPS, in which 98% (568 of 577) of the participants were reassessed to establish the eff ect of lifestyle interventions on diabetes and other related health outcomes in people at high risk for diabetes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NAhJzQb">Methods</head><p xml:id="_EX65sHh"><s xml:id="_TZDjQMR">Details of the design, methods, and population of the CDQDPS have been published previously. <ref type="bibr" target="#b1">2</ref> Briefl y, the CDQDPS investigated the eff ect of dietary and exercise intervention, alone and in combination, on incidence of type 2 diabetes in people with impaired glucose tolerance.</s><s xml:id="_kS2UkWz">In 1986, 577 adults with impaired glucose tolerance at 33 clinics in Da Qing city, China, were recruited and randomised by clinic into either a control group or one of three lifestyle interventions: diet, exercise, or diet plus exercise.</s><s xml:id="_fBwy7TB">The goal of the diet intervention was to increase participants' vegetable intake and lower their alcohol and sugar intake.</s><s xml:id="_PCkmSjC">Those who were overweight or obese were also encouraged to lose weight by reducing their total calorie intake.</s><s xml:id="_XT4FZTz">The goal of the exercise intervention was to increase leisure time physical activity.</s><s xml:id="_wxAZvtd">The eff ect of the intervention was assessed at 2-yearly intervals.</s><s xml:id="_sd2cZaD">In 1992, after a 6-year intervention, participants were informed of the fi nal results and asked to continue with normal medical care.</s></p><p xml:id="_24tGn6R"><s xml:id="_9kxpQNb">Our trial, the China Da Qing Diabetes Prevention Outcomes Study (CDQDPOS), was a longitudinal follow-up of CDQDPS participants over 20 years.</s><s xml:id="_UMKBKs9">The main objectives were to examine the intervention's long-term eff ect on the risk of diabetes, diabetes-related macrovascular and microvascular complications, and mortality.</s><s xml:id="_NZGHBSB">The primary outcomes were diabetes incidence, cardiovascular disease (CVD) incidence and mortality, all-cause morality, and any diabetes related microvascular and macrovascular complications.</s><s xml:id="_7Eah3JD">The secondary outcomes were specifi c microvascular and macrovascular diseases, risk factors for cardiovascular disease, health-related quality of life, and use of health care.</s><s xml:id="_Aq3fvut">The institutional review boards at WHO and the China-Japan Friendship Hospital approved the protocol.</s><s xml:id="_PRUKhud">All study participants or relatives who provided information about deceased participants gave written informed consent.</s></p><p xml:id="_cpykVGt"><s xml:id="_NFg3YYj">Diabetes status was defi ned by self-reported diagnosed diabetes plus evidence of raised glucose levels in the medical record, taking hypoglycaemic medications, or fasting glucose and oral glucose tolerance tests, done every 2 years during the active intervention period (1986-1992) and at the end of follow-up (2006), and interpreted using 1985 WHO criteria for diabetes. <ref type="bibr" target="#b6">7</ref></s><s xml:id="_JTA3fFJ">CVD events were defi ned as the fi rst nonfatal or fatal cardiovascular events including myocardial infarction, sudden death, stroke, or amputation.</s><s xml:id="_cb76kkf">Besides clinically diagnosed myocardial infarction, we also defi ned myocardial infarction cases on the basis of ECG results obtained during the physical examination with Minnesota codes 1</s></p><formula xml:id="formula_0">•1 or 1•2+(5•1 or 5•2) or 1•3+(5•1 or 5•2).</formula><p xml:id="_9Ent8EV"><s xml:id="_ds4H5Yk">Mortality outcomes included CVD death and all-cause death.</s><s xml:id="_Jcr4yHP">Because death certifi cates in China are not routinely retained beyond 10 years, information from multiple sources was used to determine cause of death, including available death certifi cates, history of disease, major symptoms as reported by the relative, and the cause of death assigned by the responsible physician from hospital records.</s><s xml:id="_afdCgPP">From a review of this information, two physicians, blinded to the participant's intervention, independently determined and assigned the underlying cause of death.</s><s xml:id="_uUXwHhe">A third physician (also blinded to the intervention) settled any disagreements.</s><s xml:id="_7tYz2Gt">Only a general classifi cation of cause of death was used (stroke, heart disease or any other CVD, cancer, injuries, diabetes or renal, and other).</s></p><p xml:id="_vXa2zcr"><s xml:id="_VweJPS5">Follow-up data for living participants in the Da Qing area were collected by personal interview, clinical examination, including a 75-g oral glucose tolerance tests and 12-lead electrocardiogram, and medical record review to determine diabetes and cardiovascular disease status and date of diagnosis of diabetes or cardiovascular events.</s><s xml:id="_N9HpNN9">For those outside the Da Qing area, the interview was done by phone and their local health provider did the clinical examination.</s><s xml:id="_g57cqak">For deceased participants, data were obtained by proxy interview from a living relative (spouse, sibling, or child) and medical record review.</s><s xml:id="_MXmW9rm">Trained abstracters, masked to the participant's intervention status, reviewed the medical records.</s></p><p xml:id="_9DatVeJ"><s xml:id="_km5r8BD">Our primary analysis compared diabetes incidence, CVD incidence, CVD mortality, and all-cause mortality between the control group and the combined intervention group.</s><s xml:id="_ZF6JyzQ">We combined these groups a priori because they did not diff er signifi cantly in diabetes incidence during the activeintervention period and due to concerns about statistical power.</s><s xml:id="_bxkRynA">Incidence for each outcome was calculated as the number of events divided by total person-years of exposure, with censoring at the time of the diagnosis, death, loss to follow-up, or Dec 31, 2006.</s><s xml:id="_kJ6qF8m">Hazard rate ratios (HRRs), adjusted for age and for clustering by clinic, were determined using a Weibol proportional hazards survival model.</s><s xml:id="_HTwqrDS">Age, defi ned as a continuous variable, was included in the models as a fi xed eff ect and clinic as a random eff ect.</s></p><p xml:id="_wh2tSuS"><s xml:id="_GNgysYf">577 with impaired glucose tolerance randomised by clinic 438 in intervention 138 in control In 1986 In 2006 400 alive (305 in intervention, 95 in control) 28 interview; no exam 21 interview and exam at another hospital 58 interview and exam at home 293 interview and exam at Da Qing hospital 1 lost to follow-up by 1992 142 dead (102 in intervention, 40 in control) 9 sudden death or death certificate 69 previous medical record of death-related disease 64 medical record at time of death or death certificate 34 lost to follow-up (31 in intervention, 3 in control) 26 alive 8 unknown We also assessed HRRs for CVD incidence, CVD mortality, and all-cause mortality in the post-intervention period (1993-2006).</s><s xml:id="_zPundhb">We estimated the relative risk to see whether the intervention eff ect varied during follow-up.</s><s xml:id="_tCVvzx4">We recalculated person-years of exposure from the end of the intervention (1992) through the end of follow-up (2006) by excluding the cases accrued during the intervention period (1986-1992).</s><s xml:id="_xbQsJEu">Diabetes was not included in the post-intervention analyses since 265 patients had already developed diabetes by the end of the active intervention period, thus greatly truncating and biasing the available sample entering the post-intervention period.</s><s xml:id="_RSb5wBa">The above analyses were based on intention to treat and were done with the NLMIXED procedure in SAS version 9.1.2</s><s xml:id="_X9j334r">(SAS Institute, Cary, NC, USA).</s></p><p xml:id="_PHbuvtq"><s xml:id="_f44fGBS">We also used multilevel discrete time survival models to estimate a time-varying HRR between treated and control groups, <ref type="bibr" target="#b7">8</ref> which allowed us to estimate whether the intervention eff ect deteriorated over time. <ref type="bibr" target="#b8">9</ref></s><s xml:id="_w5faHg2">The HRR was treated as a random eff ect and separate ratios for each follow-up year were estimated.</s><s xml:id="_GgpwMrz">Clinic was included in these models as a random eff ect, but age was not, since its inclusion results in data too sparse for fi tting these models.</s><s xml:id="_jYJ8hNj">Because of the randomised design, these comparisons are valid without adjusting for covariates.</s><s xml:id="_NuxSQd5">These time-varying HRR models were fi t using WinBUGS. <ref type="bibr" target="#b9">10</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3V9pyaW">Role of the funding source</head><p xml:id="_7vDFXSE"><s xml:id="_jnMyktb">Centers for Disease Control and Prevention, WHO, the China-Japan Friendship Hospital, and Da Qing First Hospital were co-sponsors of this follow-up study.</s><s xml:id="_SNUmgw7">Scientists from these organisations were involved in the study design, collection, analysis, interpretation of the data, and the writing of the report.</s><s xml:id="_aMwXkHx">The authors had full access to all data in the study and had the fi nal responsibility to submit for publication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YbbqtYj">Results</head><p xml:id="_rFJYeyG"><s xml:id="_SyHgW6T">Of the original 577 CDQDPS participants, one could not be traced at the end of the active intervention in 1992.</s><s xml:id="_PydNXsA">By 2006, 142 (25%) had died and 426 (74%) were alive on Dec 31, 2006 (fi gure 1).</s><s xml:id="_TNFjHPw">Eight could not be traced and were lost to follow-up.</s><s xml:id="_yZbaEru">For 26, only data from the active intervention period or from medical records during the post-intervention period were obtained.</s><s xml:id="_4CFQdNG">For the remainder (400), 293 were interviewed and examined at the Da Qing First Hospital and 79 were interviewed at home, of whom 58 were examined.</s><s xml:id="_QyTf8xG">For those living outside the Da Qing area (28), the interview was done by phone, and 21 of these participants were examined by their health providers.</s><s xml:id="_G2RMj3K">Of the 426 living participants, 372 (87%) had the interview and had a clinical examination.</s><s xml:id="_DFZ5ZMg">The medical records of 396 alive and 64 deceased participants were obtained.</s><s xml:id="_fmstHMr">At the end of follow-up, 153 people were eligible for oral glucose tolerance tests, but only 128 received the test and 25 had a fasting plasma glucose test at their homes.</s><s xml:id="_2xp33FU">Of the 577 CDQDPS participants, valid follow-up information was obtained for 98% (563) for diabetes, 94% (542) for any CVD events, and 98% (568) for CVD and all-cause mortality.</s><s xml:id="_YkaVscP">The total number of person-years of follow-up was 5268 for the diabetes outcome (range 1-20, median 6, IQR 11, mean 9•4 years), 8817 for the CVD-event outcome (range 1-20, median 20, IQR 7, mean 16•3 years), and 9699 for the CVD and all-cause mortality outcome (range 0•2-20, median 20, IQR 2, mean 17•9 years).</s><s xml:id="_wMQYx5W">No adverse events were recorded.</s></p><p xml:id="_b3MAuua"><s xml:id="_H7YZFcP">Participants in the intervention group were on average 2 years younger than in the control group, but there were no diff erences in baseline body-mass index, lipid, or fasting glucose levels (table <ref type="table">1</ref>).</s><s xml:id="_vw9zdpy">Diff erences in blood pressure and total cholesterol concentrations between the two groups were not signifi cant by 1992, the end of</s></p><p xml:id="_c2H3bC5"><s xml:id="_DqxCGwZ">Control Combined intervention 1986 Total (n=138) (n=438) Age (years) 46•6 (0•8) 44•7 (0•4) Sex (men/women) 79/59 233/205 Body-mass index (kg/m²) 26•2 (0•3) 25•7 (0•2) Blood pressure (mm Hg) Systolic 134•3 (2•0) 132•2 (1•1) Diastolic 88•5 (1•5) 87•2 (0•7) Total cholesterol (mmol/L) 5•26 (1•02) 5•21 (1•01) Fasting glucose (mmol/L) 5•52 (0•07) 5•60 (0•04) 2-h glucose level (mmol/L) 9•02 (0•08) 8•97 (0•02) 1992 Total (n=133) (n=397) Body-mass index (kg/m²) 25•8 (0•33) 25•2 (0•18) Blood pressure (mm Hg) Systolic 132•1 (1•8) 130•8 (1•1) Diastolic 85•0 (1•1) 85•0 (0•7) Total cholesterol (mmol/L) 5•31 (1•02) 5•26 (1•01) Fasting glucose (mmol/L) 7•58 (0•23) 7•0 (0•17) 2-h glucose level (mmol/L) 12•5 (0•48) 10•63 (0•22)* Change in body-mass index from 1986 to 1992 (kg/m²) -0•34 (0•19) -0•69 (0•10) Change in weight from 1986 to 1992 (kg) -0•89 (0•52) -1•88 (0•28) 2006 Body-mass index (kg/m²) (n=82) 24•4 (0•29) (n=266) 24•5 (0•9) Blood pressure (mm Hg) (n=87) (n=285) Systolic 145•0 (2•1) 144•6 (1•2) Diastolic 82•8 (1•3) 82•4 (0•7) Total cholesterol (mmol/L) (n=83) 5•21 (1•02) (n=262) 5•10 (1•01) Fasting glucose (mmol/L) (n=80) 8•7 (0•35) (n=260) 7•9 (0•2) † 2-h glucose level (mmol/L) (n=28) 13•8 (1•1) (n=100) 11•5 (0•50) † Change in body-mass index from 1986 to 2006 (kg/m²) (n=82) -1•57 (0•29) (n=266) -1•41 (0•18) Change in weight from 1986 to 2006 (kg) (n=82) -4•2 (0•8) (n=266) -3•7 (0•5) Data are mean (SE).</s><s xml:id="_dJrh7FR">*p&lt;0•0001.</s><s xml:id="_TUMVer7">†p&lt;0•05.</s></p><p xml:id="_dkHvU85"><s xml:id="_ZEPBhph">Table 1: Characteristics of study participants by group at baseline (1986), end of the 6-year active intervention (1992), and end of follow-up (2006) the active intervention, or by 2006 in the survivors at the end of follow-up.</s><s xml:id="_h4WPj5R">The changes in bodyweight during the active intervention period (1986-1992) and the entire follow-up period (1986-2006) did not diff er signifi cantly by group.</s></p><p xml:id="_bRxT6Vc"><s xml:id="_9Pak49k">Of the 577 participants in 1986, 435 had developed diabetes by the end of follow-up.</s><s xml:id="_xbyJgTr">265 cases were identifi ed by oral glucose tolerance tests during the active intervention phase, 145 were identifi ed by report from the patient or relative, with additional evidence of either use of hypoglycaemic medication or raised glucose level recorded in the medical record at time of diagnosis during the post-intervention period.</s><s xml:id="_rbY4ak3">Finally, 25 cases were identifi ed by oral glucose tolerance tests at the end of the study.</s><s xml:id="_QU43Ds8">The diabetes status of 14 participants was unknown.</s></p><p xml:id="_7f6ufRy"><s xml:id="_pQXfd8K">During the active intervention, the cumulative diabetes incidence was 43% in the intervention group and 66% in the control group, and the number needed to treat to prevent a case of diabetes was fi ve people (table <ref type="table">2</ref>).</s><s xml:id="_QJqaXEE">During the 20 year follow-up, the cumulative diabetes incidence was 80% in the intervention group and 93% in the control group, and the number needed to treat to prevent a case of diabetes was six people.</s><s xml:id="_asEBFuh">Participants in the intervention group had an average of 3•6 fewer years with diabetes.</s><s xml:id="_FJk24h6">In people with diabetes, comparing the active intervention group to the controls at the end of follow-up, fewer were on insulin (26% [82 of 314] vs 34% [41 of 121]) and they had lower average haemoglobin A₁ C levels (7•34% vs 7•76%), but these diff erences were not signifi cant (p=0•11 and p=0•07, respectively).</s></p><p xml:id="_z27pdgP"><s xml:id="_YJAHcWa">In multivariate analyses that controlled for age and clustering by clinic, participants in the combined intervention group had a 43% lower incidence of diabetes than those in the control group (HRR 0•57; 95% CI 0•41-0•81; table 2).</s><s xml:id="_FVmTq8k">Over 20 years, the yearly estimated HRRs ranged from 0•51 to 0•64, with intervention participants having a lower diabetes incidence throughout the study (data not shown).</s><s xml:id="_JGmBzaU">In a subanalysis of the eff ects of diet, exercise, and diet plus exercise versus control, the randomisation groups for the original study, the 20-year HRRs for diabetes were 0•58 (0•38-0•89), 0•51 (0•31-0•83), and 0•66 (0•41-1•09), respectively.</s></p><p xml:id="_CwWAsBD"><s xml:id="_ZtNvwe9">The cumulative incidence of all-cause mortality, fi rst CVD events, and CVD mortality are presented in fi gure 3.</s><s xml:id="_rrzhdgh">During the 20-year follow-up, there were 211 fi rst CVD events (145 strokes and 66 myocardial infarctions).</s><s xml:id="_vmhHkH2">There were a total of 142 deaths, of which 68 were attributed to CVD.</s><s xml:id="_MpaCQrS">No fi rst CVD events were diagnosed by ECG only, since all had been previously diagnosed clinically.</s><s xml:id="_2sbqnJe">The cumulative incidence of fi rst CVD event was 41% for intervention participants and 44% for controls (table <ref type="table">2</ref>).</s><s xml:id="_N7VQwkM">The cumulative CVD mortality rate was 28% lower in the intervention group (12%) than the control group (17%), but this diff erence was not signifi cant, nor were diff erences in all-cause mortality (25% vs 29%).</s><s xml:id="_Ef3Gufj">The estimated annual HRRs from the analysis of time-varying hazard rates ranged from 0•58 to 1•20 for fi rst CVD event, 0•61 to 0•89 for CVD-mortality, and 0•67 to 0•95 for all-cause mortality.</s></p><p xml:id="_Jkc9X47"><s xml:id="_ND3ugdQ">In the post-intervention period, the intervention group had a 8% lower incidence of fi rst CVD events (39% vs 42%), 33% lower CVD mortality (12% vs 17%), and 18% lower all-cause mortality (22% vs 27%) than the control group, Incidence per 100 person years per year (95% CI) Cumulative incidence, % (95% CI) Multivariate adjusted HRR* (95% CI) Control Intervention Control Intervention Active intervention Diabetes 1986-1992 14•1 (11•2-17•0) 7•9 (6•8-9•1) 65•8 (57•7-73•9) 42•8 (38•0-47•5) 0•49 (0•33-0•73) 1986-2006 11•3 (9•3-13•3) 6•9 (5•8-7•2) 92•8 (88•3-97•3) 79•7 (75•6-83•8) 0•57 (0•41-0•81) Any fi rst CVD events 1986-1992 0•9 (0</s></p><formula xml:id="formula_1">•2-1•6) 0•9 (0•5-1•3) 5•4 (1•5-9•2) 5•2 (3•0-7•3) 0•96 (0•76-1•44) 1986-2006 2•5 (1•9-3•2) 2•3 (1•9-2•7) 44•1 (35•3-53•0) 40•9 (36•0-45•9) 0•98 (0•71-1•37) CVD mortality 1986-1992 0 0•2 (0•0-0•3) 0 1•0 (0-1•9) - 1986-2006 0•9 (0•5-1•3) 0•6 (0•5-0•8) 17•4 (10•6-24•2) 12•5 (9•1-15•8) 0•83 (0•48-1•40) All-cause mortality 1986-1992 0•6 (0•1-1•2) 0•7 (0•8-1•1) 3•7 (0•5-6•8) 4•3 (2•3-6•2) 1•33 (0•45-3•92) 1986-2006 1•7 (1•1-2•2) 1•4 (1•1-1•6) 29•3 (21•5-37•0) 25•0 (20•8-29•2) 0•96 (0•65-1•41)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8dD9uw4">Post-intervention</head><p xml:id="_bFfpYdF"><s xml:id="_fSYGw9b">Any fi rst CVD events</s></p><formula xml:id="formula_2">1993-2006 3•2 (2•35-4•05) 2•9 (2•4-3•4) 41•9 (33•0-50•9) 38•5 (33•5-43•5) 0•98 (0•68-1•43) CVD mortality 1993-2006 0•9 (0•5-1•3) 0•6 (0•4-0•8) 17•4 (10•6-24•2) 11•6 (8•3-14•9) 0•73 (0•42-1•26) All-cause mortality 1993-2006 1•5 (1•0-2•0) 1•2 (0•9-1•4) 26•6 (</formula><p xml:id="_qGdcrnA"><s xml:id="_sTuXTDF">18•9-34•2) 21•7 (17•6-25•8) 0•90 (0•59-1•37) HRR=hazard rate ratio.</s><s xml:id="_7rSFyyt">CVD=cardiovascular disease.</s><s xml:id="_TNb7d93">*Adjusted for age and clustering by clinic.</s></p><p xml:id="_ZRnVCGb"><s xml:id="_x3AxGSS">Table 2: Incidence of diabetes, CVD, and mortality in the active intervention (1986-92) and entire follow-up period (1986-2006), and CVD and mortality in the post intervention period (1993-2006)</s></p><p xml:id="_UZ9BjjA"><s xml:id="_C42AcXM">but these diff erences were not signifi cant (table <ref type="table">2</ref>).</s><s xml:id="_n4NfeCF">The estimated HRRs from the analysis of time-varying hazard rates (data not shown) ranged from 0•58 to 1•27 for fi rst CVD event, 0•61 to 0•89 for CVD mortality, and 0•67 to 0•95 for all-cause mortality.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_CpRtkFF">Discussion</head><p xml:id="_zDWMbhG"><s xml:id="_wVkV3V4">Our fi ndings from the CDQDPOS indicate that the reduction in diabetes incidence seen during the 6-year period of active intervention persisted for two decades.</s></p><p xml:id="_7sEHquZ"><s xml:id="_xcV9q8T">Chinese participants with impaired glucose tolerance randomised to lifestyle intervention groups had a 43% lower diabetes incidence (age and clinic adjusted) for up to 14 years after the active intervention ceased, and diabetes onset was delayed an average of 3•6 years.</s><s xml:id="_5u9XsW6">These fi ndings are consistent with those of the Finnish Diabetes Prevention Study, <ref type="bibr" target="#b5">6</ref> where the relative risk reduction in diabetes incidence varied only slightly between the active intervention period and up to 3•5 years after the intervention.</s><s xml:id="_3cBgXQE">The CDQDPOS also showed that the risk of eventually developing diabetes in people with impaired glucose tolerance in the absence of intervention remains high for many years, since 93% of the controls developed diabetes over 20 years.</s><s xml:id="_TQzXbvX">Previous reports with shorter follow-up have suggested that 5-10% of those with impaired glucose tolerance develop diabetes every year, but that many revert spontaneously to normal glucose tolerance. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref></s><s xml:id="_sSbumRb">nterpretation of the fi ndings related to the intervention and CVD events and mortality is more complicated.</s><s xml:id="_GW53bsM">The incidence of fi rst CVD events and all cause mortality did not diff er signifi cantly between the combined intervention group and the control group.</s><s xml:id="_AQq9gqH">The overall adjusted HRR of death from CVD, however, was 17% lower in the intervention group, but 95% CIs were wide and the diff erence was not signifi cant.</s><s xml:id="_j9hNDfr">The observation that each of the outcomes (all-cause mortality, CVD mortality, CVD incidence) seem to have a reduced incidence for people who had received the intervention is encouraging.</s><s xml:id="_JJdCq9N">Nevertheless, our fi ndings leave the relation between lifestyle-based diabetes prevention and eff ect on CVD and mortality unresolved.</s><s xml:id="_nwHXYDS">Of the deaths due to CVD, 65% (44 of 68) were attributed to stroke and 35% to heart disease a pattern consistent with other reports from China where deaths attributable to cerebrovascular disease are particularly high. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref></s><s xml:id="_5F7M7J8">ince the original CDQDPS was not designed to examine the eff ects of intervention on vascular complications and mortality, the statistical power to detect reductions in incidence of CVD and mortality risk was restricted.</s><s xml:id="_dz6x3QW">Only a few studies have examined the eff ect of interventions for diabetes prevention on CVD.</s><s xml:id="_CxuUP48">In people with impaired glucose tolerance, only the STOP-NIDDM study <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16</ref> using acarbose, and the 12-year follow-up of the Malmö study <ref type="bibr" target="#b16">17</ref> using diet and tolbutamide, suggest that the incidence of CVD could be reduced with interventions that decrease the incidence of diabetes.</s></p><p xml:id="_auDCBGG"><s xml:id="_2KNEQGD">Other long-term follow-up trials might provide conclusive answers to this question. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b17">18</ref></s><s xml:id="_A5HQyVD">he extended reductions in diabetes incidence seen in intervention participants in our study could be explained by three broad mechanisms.</s><s xml:id="_x3RXpMv">First, lifestyle interventions could have led to changes in usual behaviour that were maintained beyond the period of the study intervention.</s><s xml:id="_sDvewVA">Second, the interventions might have led to changes in the preventive care and health promotion eff orts provided</s></p><p xml:id="_AcPes2J"><s xml:id="_hc8GRxh">Cumulative incidence of all-cause death 0 5 10 15 20 25 30 35 Percentage 329 345 362 379 388 396 405 414 422 432 432 97 101 105 110 115 120 128 131 133 135 136 Cumulative incidence of first CVD event 0 5 10 15 20 25 30 35 40 45 Percentage 252 279 299 323 340 356 378 388 395 403 409 79 86 93 100 108 119 123 126 128 131 133 Cumulative incidence of CVD death 0 0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 4 6 8 10 12 14 16 18 Percentage 385 392 401 409 416 418 424 428 430 432 432 115 118 121 122 127 130 133 Years of follow-up 136 136 136 136 Number at risk Control Intervention Number at risk Control Intervention Number at risk Control Intervention by community clinics that had eff ects beyond the intervention period.</s><s xml:id="_GPEHgJ7">Finally, lifestyle intervention might lead to some type of metabolic memory.</s><s xml:id="_uFCFPQm">Eff ects on insulin secretion or sensitivity that are well documented over the short term <ref type="bibr" target="#b18">19</ref> might be maintained well beyond the active intervention in a manner analogous to the persistent changes that follow intensive insulin treatment for people with type 1 diabetes. <ref type="bibr" target="#b19">20</ref></s><s xml:id="_myM7W2T">ollow-up analyses of the Finnish Diabetes Prevention Study and the US Diabetes Prevention Program each suggested that weight-change was the mechanism for explaining reduced diabetes incidence. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b20">21</ref></s><s xml:id="_XSEVQsB">However, we found little diff erence in weight-change between the intervention and control conditions during the active intervention, and we note that weight-change was also small in other successful prevention trials in other Asian populations. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b4">5</ref></s><s xml:id="_KzB7awr">Further analyses will be needed to establish whether exercise and diet reduce the incidence of type 2 diabetes independently of weight-change or by changing body composition, which might not be indicated by changes in bodyweight.</s></p><p xml:id="_BfhcSxS"><s xml:id="_9pdgYrS">The CDQDPS was designed to investigate whether lifestyle interventions delivered to groups, rather than to individuals, could reduce the incidence of diabetes.</s><s xml:id="_Wfz8cFs">The study, therefore, adopted a randomised cluster design, randomising participants on the basis of the clinics where they received their usual medical care.</s><s xml:id="_NkMPbKV">This design not only allowed for group instruction, but limited the possibility that participants in the active intervention groups could infl uence the behaviour of those in the control groups.</s><s xml:id="_KNDxbAP">This study used intervention techniques that needed few resources and could be applied to large populations.</s><s xml:id="_qQKm4v7">For analysis of the long-term eff ects of the interventions we decided a priori to pool groups of patients who had received diet, exercise, and diet plus exercise, because each of these interventions reduced diabetes incidence to a similar extent during the 6-year active intervention.</s><s xml:id="_fpSXrxA">Detailed subanalysis of the 20-year follow-up indicates that three intervention groups enjoyed similar long-term benefi ts, providing an additional post hoc justifi cation for pooling these groups.</s></p><p xml:id="_KnMcjHR"><s xml:id="_3uavyH9">The high rates of ascertainment of the vital status of participants 14 years after the end of the active intervention, and inclusion of 94% of participants still living 20 years after randomisation, reduced any selective biases that might be attributable to loss to follow-up.</s><s xml:id="_7EKubvh">Furthermore the follow-up interviews, examinations, and endpoint assessments were done by staff members who were unaware of the groups to which the participants were originally assigned, thus keeping interview or examiner bias to a minimum.</s></p><p xml:id="_JkdWxYs"><s xml:id="_r4ZmPHb">The main limitation of the CDQDPOS is that, beyond the 6-year active interventions, the participants were not re-tested periodically using standardised procedures.</s><s xml:id="_2Re3Tuw">This passive ascertainment explains at least in part why we observed a lower diabetes incidence in the post-intervention period.</s><s xml:id="_QpHBfvx">The lower incidence rate of diabetes in the follow-up period than during the active intervention could also be because the people at highest risk had already converted or died sooner, leaving a lower risk pool of participants to convert at a slower rate during the extended follow-up.</s><s xml:id="_sUkWFcd">However, because the same ascertainment approach was used in the intervention and control groups, with an oral glucose tolerance test at the end of the study, passive ascertainment is unlikely to have led to a bias in our fi ndings.</s><s xml:id="_y5MX2yu">Underlying causes of death were ascertained largely from proxy interviews supplemented by review of medical records, but the reports of causes of death within our broad categories seem unlikely to be biased by treatment group.</s><s xml:id="_qtse9ab">There were no signifi cant diff erences in the response rates to the questionnaire, medical record review, and physical examination by treatment assignments, and the percentage with events confi rmed by medical record did not diff er by vital status.</s></p><p xml:id="_daFMs2N"><s xml:id="_7TcQPW2">The lack of systematic clinical measurements during follow-up limited our ability to examine the eff ect of diff erent risk factor changes and medical interventions on the study outcomes.</s><s xml:id="_wu3dbp2">Although data for some risk factors were obtained for survivors at the fi nal visit, this information was potentially aff ected by survival bias and eff ects of treatment for comorbid conditions.</s><s xml:id="_pPQ7uqg">Detailed information related to lifestyle changes was not obtained beyond the period of active intervention.</s><s xml:id="_uHubQW9">Thus, we do not have data for weight and behaviour changes during follow-up, preventing conclusions about the contributions of changes in physical activity, weight, diet, or medications on outcomes.</s><s xml:id="_NpjJghd">In 2006, surviving participants in the intervention and control groups reported no diff erences in total calorie intake from the main food items or amount of leisure time physical activity in the past year (data not shown).</s><s xml:id="_dcnXm9h">Although we achieved a 43% reduction in diabetes incidence in the intervention group, 80% of them still developed diabetes, albeit some 3•6 years later than the control group.</s><s xml:id="_2k63hnc">Had the active period of intervention been for longer, then perhaps diabetes would have been averted in more of the participants.</s></p><p xml:id="_pFSfSfX"><s xml:id="_6HaGuRD">The CDQDPOS has shown that, in Chinese people with impaired glucose tolerance, group-based interventions targeting lifestyle changes such as diet and exercise produce a durable and long-lasting reduction in incidence of type 2 diabetes.</s><s xml:id="_DpPBqyC">Our fi ndings and the results from the 3-year follow-up of the Finnish Diabetes Prevention Study 6 suggest that the durable eff ects of lifestyle interventions extend across cultures.</s><s xml:id="_fznGSYC">There were 33•2 million people with impaired glucose tolerance in China in 2003 and this amount is expected to increase to 54•3 million by 2025. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_H46TK7u">Small group and lifestyle counselling in high-risk individuals at community facilities is likely to be eff ective if aimed more broadly at the Chinese population, and might also be necessary in light of obesity trends in China. <ref type="bibr" target="#b22">23</ref></s><s xml:id="_zWqaGw7">At a more global level, widespread adoption of such interventions off ers the prospect that projected increases in type 2 diabetes could be attenuated.</s><s xml:id="_rkBtv2X">Since around 3 million excess deaths a year are attributable to diabetes worldwide, <ref type="bibr" target="#b23">24</ref> lifestyle interventions seem to be a justifi able public health action both in developed and developing nations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2Y8mWbV">Contributors</head><p xml:id="_AdTWA7S"><s xml:id="_2qR2tMy">GL and PZ coordinated the study and contributed to acquisition of funding, study design, statistical analysis, and draft and revision of the paper.</s><s xml:id="_Xk4xfar">JW and QG contributed to study design, acquisition of data, and statistical analysis.</s><s xml:id="_2xuUbcY">EWG contributed to study design, acquisition of funding, statistical analysis, and draft and revision of the paper.</s><s xml:id="_qQS3hZT">WY contributed to study design.</s><s xml:id="_Z7v9awY">GL, HuL, HoL, YJ YS, BZ, and JZ contributed to acquisition of data.</s><s xml:id="_dN9x2zf">YA contributed to acquisition of data and statistical analysis.</s><s xml:id="_7ec4REx">TJT contributed to statistical analysis and draft of the paper.</s><s xml:id="_rCNv7tf">RBG contributed to statistical analysis and revision of the paper.</s><s xml:id="_s3j2Mkb">GR contributed to study design, acquisition of funding, and revision of the paper.</s><s xml:id="_KDyWc8b">YH contributed to study design and acquisition of data.</s><s xml:id="_3wc68sv">PHB contributed to study design, statistical analysis, and draft and revision of the paper.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WtQUvZe">Confl ict of interest statement</head><p xml:id="_ctpyR23"><s xml:id="_C7cDUnJ">We declare that we have no confl ict of interest.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p xml:id="_MT55v6n"><s xml:id="_3UnPe9J">Figure 1: Trial profi le</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p xml:id="_qsE2VHn"><s xml:id="_fVNXceb">Figure 2: Cumulative incidence of diabetes mellitus during follow-up in China Da Qing Diabetes Prevention Outcome Study</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>20 -Figure 3 :</head><label>203</label><figDesc><div><p xml:id="_RUCrjYJ"><s xml:id="_heMPNE6">Figure 3: Cumulative incidence of all-cause mortality (A), fi rst CVD event (B), and CVD mortality (C) during follow-up in China Da Qing Diabetes Prevention Outcome Study</s></p></div></figDesc></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_VPkaTgF">Acknowledgments</head><p xml:id="_SS2xkaC"><s xml:id="_ASYsVuQ">We thank the study participants in the original <rs type="projectName">China Da Qing Diabetes Prevention Study</rs> and the <rs type="projectName">China Da Qing Diabetes Prevention Outcome Study</rs>.</s><s xml:id="_gqW7c9N">This study was partially funded by <rs type="funder">CDC/WHO Cooperative Agreement</rs> number <rs type="grantNumber">U58/CCU424123-01-02</rs>.</s><s xml:id="_CGV4pk9">We also thank <rs type="person">Lingzhi Kong</rs>, <rs type="institution">China Ministry of Health</rs>, and the leadership at the <rs type="institution">China-Japan Friendship Hospital</rs>, <rs type="institution">Da Qing First Hospital</rs>, the <rs type="institution">Da Qing City Health Bureau, West Pacifi c Regional Offi ce of WHO</rs>, and the <rs type="institution">WHO Beijing Offi ce</rs> for their general support.</s><s xml:id="_yR6Yj3N">We also thank <rs type="person">Michael M Engelgau</rs> for his contribution to study design and <rs type="person">David F Williamson</rs> for his constructive comments on the earlier version of the paper.</s><s xml:id="_Z3Rpcn3">Our special thanks go to the late <rs type="person">Professor Pan Xiao Ren</rs> who originated the <rs type="affiliation">China Da Qing Diabetes Prevention Study</rs>, as without his leadership this study would not have been possible.</s><s xml:id="_sZs9wrQ">The fi ndings and conclusions in this report are those of the authors and do not necessarily represent the views of the <rs type="institution">Centers for Disease Control and Prevention</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funded-project" xml:id="_gE3W6Gs">
					<orgName type="project" subtype="full">China Da Qing Diabetes Prevention Study</orgName>
				</org>
				<org type="funded-project" xml:id="_FPZdfJV">
					<idno type="grant-number">U58/CCU424123-01-02</idno>
					<orgName type="project" subtype="full">China Da Qing Diabetes Prevention Outcome Study</orgName>
				</org>
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_Vf2hYAY">Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Knowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Barrett-Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Fowler</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa012512</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cEmM2MK">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="393" to="403" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_QXype76">Eff ects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">R</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Hu</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.20.4.537</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YS8Wt7s">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="537" to="544" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pan XR, Li GW, Hu YH, et al. Eff ects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_p57XxsA">The Indian Diabetes Prevention Programme shows that lifestyle modifi cation and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ramachandran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Snehalatha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mukesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Bhaskar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vijay</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00125-005-0097-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AhZxAkW">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="289" to="297" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modifi cation and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-97.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_E3sbcs5">Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tuomilehto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lindstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Eriksson</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm200105033441801</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NSxThps">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="page" from="1343" to="1350" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_BKfS56s">Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kosaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Noda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuzuya</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2004.06.010</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SkVFFYu">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="152" to="162" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152-62.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_x3tCDdS">Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lindstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ilanne-Parikka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peltonen</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(06)69701-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JFjaKYK">Lancet</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1673" to="1679" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-79.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main" xml:id="_Zz2XHeH">Diabetes mellitus: report of a WHO study group</title>
		<author>
			<persName><surname>Who</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1985">1985</date>
			<publisher>World Health Organization</publisher>
			<pubPlace>Geneva</pubPlace>
		</imprint>
	</monogr>
	<note type="report_type">Technical report series 727</note>
	<note type="raw_reference">WHO. Diabetes mellitus: report of a WHO study group. Technical report series 727. Geneva: World Health Organization, 1985.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_M5mm5hZ">Logistic regression, survival analysis, and the Kaplan-Meier curve</title>
		<author>
			<persName><forename type="first">B</forename><surname>Efron</surname></persName>
		</author>
		<idno type="DOI">10.2307/2288857</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GwWgyhA">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="414" to="425" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Efron B. Logistic regression, survival analysis, and the Kaplan-Meier curve. J Am Stat Assoc 1988; 83: 414-25.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main" xml:id="_KNyrWKJ">Data analysis using regression and multilevel/hierarchical models</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gelman</surname></persName>
		</author>
		<author>
			<persName><surname>Hj</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
			<publisher>Cambridge University Press</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Gelman A HJ. Data analysis using regression and multilevel/hierarchical models. New York: Cambridge University Press, 2007.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_P9rC9DW">WinBUGSa Bayesian modelling framework: concepts, structure, and extensibility</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Best</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spiegelhalter</surname></persName>
		</author>
		<idno type="DOI">10.1023/a:1008929526011</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tTSakwm">Stat Comput</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="325" to="337" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS- a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325-37.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_fJtW2J9">Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Santaguida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raina</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2007.05.004</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NWWzEQY">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="305" to="312" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305-12.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_vbxwt3R">The natural history of impaired glucose tolerance in the Pima Indians</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Saad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Knowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pettitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Bennett</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm198812083192302</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_C9dR6WH">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="page" from="1500" to="1506" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1988; 319: 1500-06.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_Rj3VcQb">Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhao</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.cir.103.3.462</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_U6dEJXv">Circulation</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="462" to="468" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wu Z, Yao C, Zhao D, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring. Circulation 2001; 103: 462-68.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_86QFwSd">Major causes of death among men and women in China</title>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmsa050467</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Pz8RbXt">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="1124" to="1134" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-34.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_GnD5f9a">Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Chiasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Josse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gomis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hanefeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Karasik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laakso</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.290.4.486</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bak2Bg5">JAMA</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="486" to="494" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_qdDurAx">Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Chiasson</surname></persName>
		</author>
		<idno type="DOI">10.4158/ep.12.s1.25</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7WsxZUx">Endocr Pract</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="25" to="30" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>suppl</note>
	<note type="raw_reference">Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006; suppl 1: 25-30.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_b9QHfGS">Glucose tolerance and mortality, including a substudy of tolbutamide treatment</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Knowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sartor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Melander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schersten</surname></persName>
		</author>
		<idno type="DOI">10.1007/s001250050734</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jeJqYMV">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="680" to="686" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Knowler WC, Sartor G, Melander A, Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997; 40: 680-86.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_vQbNVT5">The Diabetes Prevention Program: recruitment methods and results</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Marrero</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0197-2456(01)00184-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_D6HBmxu">Control Clin Trials</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="157" to="171" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rubin RR, Fujimoto WY, Marrero DG, et al. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials 2002; 23: 157-71.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_xdZNv6M">Exercise-induced increase in muscle insulin sensitivity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Holloszy</surname></persName>
		</author>
		<idno type="DOI">10.1152/japplphysiol.00123.2005</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZSCSEx8">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="338" to="343" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Holloszy JO. Exercise-induced increase in muscle insulin sensitivity. J Appl Physiol 2005; 99: 338-43.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_3B9N3ye">Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained eff ect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study</title>
		<idno type="DOI">10.1001/jama.290.16.2159</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KXDKqNV">JAMA</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="2159" to="2167" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained eff ect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-67.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_uZM2suw">Eff ect of weight loss with lifestyle intervention on risk of diabetes</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Hamman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Wing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Edelstein</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc06-0560</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cDHMWP5">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2102" to="2107" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hamman RF, Wing RR, Edelstein SL, et al. Eff ect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102-07.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main" xml:id="_T37cdM9">Diabetes Atlas, Third Edition</title>
		<idno type="DOI">10.1016/s1499-2671(08)24263-2</idno>
		<ptr target="http://www.eatlas.idf.org/media/" />
		<imprint>
			<date type="published" when="2006-08-04">2006. Aug 4, 2008</date>
			<publisher>International Diabetes Federation</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">International Diabetes Federation. Diabetes Atlas, Third Edition, 2006. http://www.eatlas.idf.org/media/ (accessed Aug 4, 2008)</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_fKvtcQB">Overweight and obesity in China</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.333.7564.362</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j4cBzvb">BMJ</title>
		<imprint>
			<biblScope unit="volume">333</biblScope>
			<biblScope unit="page" from="362" to="363" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wu YF. Overweight and obesity in China. BMJ 2006; 333: 362-63.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_q8z5cHV">The burden of mortality attributable to diabetes: realistic estimates for the year 2000</title>
		<author>
			<persName><forename type="first">G</forename><surname>Roglic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Unwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Bennett</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.28.9.2130</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4cSt3xb">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2130" to="2135" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130-35.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
